The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling
- 14 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (17), 3519-3529
- https://doi.org/10.1158/0008-5472.can-20-0216
Abstract
Colorectal cancer (CRC) exhibits aberrant activation of Wnt/beta-catenin signaling. Many inhibitors of the Wnt/beta-catenin pathway have been tested for Wnt-dependent cancers including CRC but are unsuccessful due to severe adverse reactions. FL3 is a synthetic derivative of natural products called flavaglines, which exhibit anti-inflammatory and cytoprotective properties in intestinal epithelial cells, but has not been previously tested in cell or pre-clinical models of intestinal tumorigenesis. In vitro studies suggest that flavaglines target Prohibitin 1 (PHB1) as a ligand, but this has not been established in the intestine. PHB1 is a highly conserved protein with diverse functions that depend on its post-translational modifications and subcellular localization. Here we demonstrate that FL3 combats intestinal tumorigenesis in the azoxymethane-dextran sodium sulfate and ApcMin/+ mouse models and in human CRC tumor organoids (tumoroids) by inhibiting Wnt/beta-catenin signaling via induction of Axin1 expression. FL3 exhibited no change in cell viability in normal intestinal epithelial cells or human matched-normal colonoids. FL3 response was diminished in CRC cell lines and human CRC tumoroids harboring a mutation at S45 of beta-catenin. PHB1 deficiency in mice or in human CRC tumoroids abolished FL3-induced expression of Axin1 and drove tumoroid death. In CRC cells, FL3 treatment blocked phosphorylation of PHB1 at Thr258, resulting in its nuclear translocation and binding to the Axin1 promoter. These results suggest that FL3 inhibits Wnt/beta-catenin signaling via PHB1-dependent activation of Axin1. FL3 therefore represents a novel compound that combats Wnt pathway-dependent cancers such as CRC.Other Versions
Funding Information
- Baylor Scott & White Research Institute (R01-DK117001)
- Litwin IBD Pioneers Crohn's Colitis Foundation (301869)
This publication has 49 references indexed in Scilit:
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumGut, 2012
- Raf activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in the raft domain of the plasma membraneOncogene, 2012
- Generating intestinal tissue from stem cells: potential for research and therapyRegenerative Medicine, 2011
- Flavaglines Alleviate Doxorubicin Cardiotoxicity: Implication of Hsp27PLOS ONE, 2011
- Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markersFunctional & Integrative Genomics, 2011
- Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core proteinHepatology, 2009
- Phospho-regulation of β-Catenin Adhesion and Signaling FunctionsPhysiology, 2007
- Prohibitin protects against oxidative stress in intestinal epithelial cellsThe FASEB Journal, 2006
- Camptothecin Induces Nuclear Export of Prohibitin Preferentially in Transformed Cells through a CRM-1-dependent MechanismOnline Journal of Public Health Informatics, 2006
- A Synthetic Derivative of the Natural Product Rocaglaol Is a Potent Inhibitor of Cytokine-Mediated Signaling and Shows Neuroprotective Activity in Vitro and in Animal Models of Parkinson's Disease and Traumatic Brain InjuryMolecular Pharmacology, 2005